Orion Corporation

Orion Corporation
Native name	Orion Oyj
Type	Julkinen osakeyhtiö
Traded as	Nasdaq Helsinki: ORNAV,ORNBV
Industry	Pharmaceutical industry
Founded	1917
Headquarters	Espoo, Finland
Key people	Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman)
Products	Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests
Revenue	€1.074 billion (2016)
Operating income	€315 million (2016)
Net income	€249 million (2016)
Total assets	€1.063 billion (2016)
Total equity	€641 million (2016)
Number of employees	3,446 (2016)
Website	www.orion.fi/en
	Footnotes / references;

Orion Corporation (Finnish: Orion Oyj),^[2]^[3] founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

Products

Antiparkinson agents

Comtan/Comtess (entacapone)
Stalevo (entacapone, carbidopa, levodopa)
Eldepryl (selegiline)

Animal surgical anesthetics and analgesics

Dexdomitor (dexmedetomidine)
Domitor (medetomidine)
Domosedan (detomidine)
Antisedan (atipamezole)

Antiandrogens

Nubeqa (darolutamide)

Analgesics

Indalgin (indometacin, ethylmorphine)
Dexdor (dexmedetomidine)
Para-Tabs (paracetamol)
Generic drug of pregabalin

NSAIDs

Burana (ibuprofen)
Ketorin (ketoprofen)
Pronaxen (naproxen)

Anti-diabetic drugs

Glimepirid Orion (glimepiride)
Metforem (metformin)
Origlucon (glibenclamide)

Gastric acid related drugs

Ranimex (ranitidine)
Zolt (lansoprazole)

Oral hygiene

Daktarin (miconazole)
Elmex (olaflur)

Motion sickness drugs

Vertipam (cyclizine, diazepam and nicotinic acid)

Vitamins

Cohemin (cyanocobalamin)
Neuramin (thiamine)

Anticoagulants

Marevan (warfarin)

Cardiovascular drugs

Digoxin (digoxin)
Disomet (disopyramide)
Dopmin (dopamine)
Kiniduron (quinidine)
Lidocard (lidocaine)
Nitro (glyceryl trinitrate)
Nitrosid (isosorbide dinitrate)
Ormox (isosorbide mononitrate)

Antihypertensive drugs

Amlodipin Orion (amlodipine)
Carvedilol Orion Pharma (carvedilol)
Dilzem (diltiazem)
Escor (nilvadipine)
Espesil (acebutolol)
Lisipril (lisinopril)
Lopril (captopril)
Nifangin (nifedipine)
Orloc (bisoprolol)
Pinloc (pindolol)
Pratsiol (prazosin)
Propral (propranolol)
Selopral (metoprolol)
Verpamil (verapamil)
Lisipril Comp (lisinopril and hydrochlorothiazide)
Orloc Comp (bisoprolol and hydrochlorothiazide)

Inotropic drugs

Simdax (levosimendan)

Diuretics

Diurex (hydrochlorothiazide and amiloride)
Furesis (furosemide)
Furesis Comp (furosemide and triamterene)
Hydrex (hydrochlorothiazide)
Indapamide Orion (indapamide)
Spiresis (spironolactone)
Uretren Comp (trichlormethiazide and triamterene)

Hypolipidemic agents

Atorvastatin Orion (atorvastatin)
Lovacol (lovastatin)
Pravastatin Orion (pravastatin)
Simvastatin Orion (simvastatin)

References

^ https://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf
^ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
^ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.

External links

Official website

[1] ttps://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf

[bis_orion-2] "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.

[orion_bylaws-3] "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.

[1]

[2]

[3]


Native name	Orion Oyj
Type	Julkinen osakeyhtiö
Traded as	Nasdaq Helsinki: ORNAV,ORNBV
Industry	Pharmaceutical industry
Founded	1917
Headquarters	Espoo, Finland
Key people	Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman)
Products	Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests
Revenue	€1.074 billion (2016)
Operating income	€315 million (2016)
Net income	€249 million (2016)
Total assets	€1.063 billion (2016)
Total equity	€641 million (2016)
Number of employees	3,446 (2016)
Website	www.orion.fi/en
Footnotes / references ^[1]